Develops genetic medicines for hemophilia A and cardiometabolic diseases.
Mar 2026Revenue $22.3M/yrExpenses $115M/yr
No trendCash runway ≈ 1.4 years from Jun 2026
Figures by year
When will Metagenomi Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2026, revenue was $22.3M and expenses $115M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $25.2M | $121M | −$96.0M |
| Dec 2024 | $52.3M | $141M | −$88.9M |
| Dec 2023 | $44.8M | $123M | −$78.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.